Internal Medicine Alert
RSSArticles
-
Carbohydrates, Insulin, and Obesity
Carbohydrate intake stimulates insulin secretion, which is the primary driver of weight gain. Besides driving glucose into cells, insulin causes fat storage, increases hunger, and lowers energy expenditure. High insulin blood levels lead to obesity with some genetic variation.
-
Biventricular Hypertrophy in an Asymptomatic Patient?
-
Eravacycline Injection (Xerava)
The FDA has approved a new parenteral, broad-spectrum antibiotic in the tetracycline class for the treatment of complicated intra-abdominal infections.
-
Home-based Detection of Undiagnosed Atrial Fibrillation
In patients with risk factors for atrial fibrillation, screening with a self-applied wearable ECG patch resulted in significantly increased rates of new atrial fibrillation diagnoses within four months, along with greater use of anticoagulants and healthcare resources.
-
Are In-hospital Deaths Related to Community-acquired Pneumonia Preventable?
This secondary analysis of data from five tertiary care centers found that among patients hospitalized for community-acquired pneumonia, very few deaths potentially were related to a lapse in in-hospital quality of pneumonia care.
-
Revised Anticoagulation Therapy Guidelines for Atrial Fibrillation Patients
More patients with atrial fibrillation may receive anticoagulation, according to new recommendations.
-
Elagolix (Orilissa)
Elagolix is indicated for the management of moderate to severe pain associated with endometriosis.
-
Treatment of Chronic Subdural Hematoma With Atorvastatin
The results of a recent study suggest that atorvastatin may be a safe and effective nonsurgical alternative for patients with chronic subdural hematoma.
-
Inappropriate Outpatient Antibiotic Prescribing: The Need to Target Urgent Care Centers
Urgent care centers, which are part of a growth industry, are responsible for a large proportion of antibiotic prescriptions, including inappropriate prescriptions for acute respiratory diagnoses.
-
Latent Tuberculosis Treatment With 4 Months of Rifampin Compared to 9 Months of Isoniazid
In an open-label trial, adults with latent tuberculosis infection were randomized to either four months of treatment with rifampin or nine months of treatment with isoniazid. The four-month rifampin regimen was non-inferior to nine months of isoniazid for prevention of active tuberculosis.